{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T03:10:04Z","timestamp":1774408204189,"version":"3.50.1"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T00:00:00Z","timestamp":1615420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>To compare metabolic effects of modified release hydrocortisone (MR-HC) with standard hydrocortisone (HC) therapies in adults with Adrenal Insufficiency (AI).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Adult patients (n = 12) with AI, established on HC therapy, were recruited from Endocrinology clinics at University Hospitals Coventry and Warwickshire (UHCW), UK. Baseline (HC) metabolic assessments included fasting serum HbA1C, lipid and thyroid profiles, accurate measures of body composition (BodPod), and 24-h continuous measures of energy expenditure including Sleeping Metabolic Rate (SMR) using indirect calorimetry within the Human Metabolism Research Unit, UHCW. All participants then switched HC to MR-HC with repeat (MR-HC) metabolic assessments at 3 months. Paired-sample t-tests were used for data comparisons between HC and MR-HC assessments: P-value &amp;lt;0.05 was considered significant.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Following exclusion of 2 participants, analyses were based on 10 participants. Compared with baseline HC data, following 3 months of MR-HC therapy mean fat mass reduced significantly by \u22123.2 kg (95% CI: \u22126.0 to \u22120.4). Mean (SD) baseline HC fat mass vs repeat MR-HC fat mass: 31.9\u00a0kg (15.2) vs 28.7\u00a0kg (12.8) respectively, P = 0.03. Mean SMR increased significantly by +77 kcal\/24\u00a0h (95% CI: 10\u2013146). Mean (SD) baseline HC SMR vs repeat MR-HC SMR: 1,517 kcal\/24\u00a0h (301) vs 1,594 kcal\/24\u00a0h (344) respectively, P = 0.03. Mean body fat percentage reduced significantly by \u22123.4% (95% CI: \u22126.5 to \u22120.2). Other measures of body composition, energy expenditure, and biochemical analytes were equivalent between HC and MR-HC assessments.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In adults with AI, switching from standard HC to MR-HC associates with early metabolic benefits of reduced fat mass and increased SMR.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2021.641247","type":"journal-article","created":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T09:30:23Z","timestamp":1615455023000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Early Metabolic Benefits of Switching Hydrocortisone to Modified Release Hydrocortisone in Adult Adrenal Insufficiency"],"prefix":"10.3389","volume":"12","author":[{"given":"Christopher A. M.","family":"Bannon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Border","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Hattersley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin O.","family":"Weickert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Grossman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harpal S.","family":"Randeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas M.","family":"Barber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,11]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","DOI":"10.1016\/B978-0-12-801238-3.99423-6","article-title":"Adrenal Insufficiency: Etiology and Diagnosis","volume-title":"Encyclopedia of Endocrine Diseases","author":"Nicolaides","year":"2018"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61684-0","article-title":"Adrenal insufficiency","volume":"383","author":"Charmandari","year":"2014","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.17-3-258","article-title":"Adrenal insufficiency \u2013 recognition and management","volume":"17","author":"Pazderska","year":"2017","journal-title":"Clin Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1530\/EC-18-0418","article-title":"Glucocorticoid management of adrenal insufficiency in the United Kingdom: assessment using real-world data","volume":"8","author":"Iqbal","year":"2019","journal-title":"Endocr Connect"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12653","article-title":"Variation in absorption and half-life of hydrocortisone influence plasma cortisol concentrations","volume":"82","author":"Hindmarsh","year":"2015","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.metabol.2017.02.005","article-title":"Pharmacokinetics of oral hydrocortisone - Results and implications from a randomized controlled trial","volume":"71","author":"Werumeus Buning","year":"2017","journal-title":"Metabolism"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-36-6-1043","article-title":"Diurnal Variation of the Metabolic Clearance Rate of Cortisol. Effect on Measurement of Cortisol Production Rate","volume":"36","author":"de Lacerda","year":"1973","journal-title":"J Clin Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-0076","article-title":"Premature mortality in patients with Addison\u2019s disease: a population-based study","volume":"91","author":"Bergthorsdottir","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2003.12.036","article-title":"Long-term mortality in the United States cohort of pituitary-derived growth hormone recipients","volume":"144","author":"Mills","year":"2004","journal-title":"J Pediatr"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-17-0154","article-title":"Management of endocrine disease: risk of overtreatment in patients with adrenal insufficiency: current and emerging aspects","volume":"177","author":"Mazziotti","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-09-0170","article-title":"Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study","volume":"161","author":"Johannsson","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-1926","article-title":"Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation","volume":"97","author":"Johannsson","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B13","volume-title":"Plenadren 5 mg and 20 mg modified release tablets","year":"2019"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13999","article-title":"Improving glucocorticoid replacement profiles in adrenal insufficiency","volume":"91","author":"Choudhury","year":"2019","journal-title":"Clin Endocrinol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14275","article-title":"Systematic Review and Meta-Analysis of the Metabolic Effects of Modified-Release Hydrocortisone versus Standard Glucocorticoid Replacement Therapy in Adults with Adrenal Insufficiency","volume":"93","author":"Bannon","year":"2020","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30398-4","article-title":"Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): a single-blind, randomised controlled trial","volume":"6","author":"Isidori","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1159\/000110621","article-title":"Long-acting hydrocortisone for glucocorticoid replacement therapy","volume":"68","author":"Johannsson","year":"2007","journal-title":"Horm Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-14-0327","article-title":"Prospective evaluation of long-term safety of dual-release hydrocortisone replacement administered once daily in patients with adrenal insufficiency","volume":"171","author":"Nilsson","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/jc.2018-00346","article-title":"Circadian rhythm of glucocorticoid administration entrains clock genes in immune cells: A DREAM trial ancillary study","volume":"103","author":"Venneri","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12652","article-title":"Enhanced thermic effect of food, postprandial NEFA suppression and raised adiponectin in obese women who eat slowly","volume":"82","author":"Reddy","year":"2015","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/75.3.453","article-title":"Body-composition assessment via air-displacement plethysmography in adults and children: a review","volume":"75","author":"Fields","year":"2002","journal-title":"Am J Clin Nutr"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60812-X","article-title":"Quantification of the effect of energy imbalance on bodyweight","volume":"378","author":"Hall","year":"2011","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1994.tb03007.x","article-title":"The effect of pharmacological dosages of glucocorticoids on free living total energy expenditure in man","volume":"40","author":"Chong","year":"1994","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.1996.271.2.E317","article-title":"Effects of glucocorticoids on energy metabolism and food intake in humans","volume":"271","author":"Tataranni","year":"1996","journal-title":"Am J Physiol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1530\/EJE-15-1212","article-title":"Achieving a physiological cortisol profile with once-daily dual-release hydrocortisone: a pharmacokinetic study","volume":"175","author":"Johannsson","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-20-0066","article-title":"Fixing the broken clock in adrenal disorders: focus on glucocorticoids and chronotherapy","volume":"246","author":"Minnetti","year":"2020","journal-title":"J Endocrinol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.35.3.758","article-title":"Acute suppression of muscle sympathetic nerve activity by hydrocortisone in humans","volume":"35","author":"Dodt","year":"2000","journal-title":"Hypertension"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.641247\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T09:30:26Z","timestamp":1615455026000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.641247\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,11]]},"references-count":27,"alternative-id":["10.3389\/fendo.2021.641247"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2021.641247","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,11]]},"article-number":"641247"}}